In contrast, tumor recurrence was observed in one out of five shLAPTM5 tumors after initial shrinkage due to temozolomide treatment (Figure 3B), supporting that LAPTM5 sensitized the CD40-positive U87MG tumor cells to temozolomide. Here, CD40 is linked to neoplasm.